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A B S T R A C T
The development of an eﬀective amphotericin B (AmB) topical formulation to replace the systemically toxic
injections currently used in cutaneous leishmaniasis (CL) treatment is challenging due to poor absorption
through the skin. Aiming at an eﬀective local chemotherapy, we designed PLGA (poly(lactide-co-glycolide acid)
microparticles loaded with deoxycholate amphotericin B (d-AmB) for both macrophage intracellular targeting
and sustained extracellular release. For that, d-AmB/PLGA microparticles with sizes ranging from 0.5 μm to
20 μm were synthesized and tested both in vitro and in vivo. In vitro, d-AmB/PLGA was more selectively active
against intracellular amastigotes of Leishmania amazonensis than free d-AmB (selectivity index= 50 and 25,
respectively). In vivo, the eﬃcacy of a single intralesional (i.l) injection with d-AmB/PLGA was determined in
early and established BALB/c mouse ear lesions. In early lesions, a single injection given on day 10 of infection
was more eﬀective in controlling parasite growth than eight i.l. injections with free d-AmB, as measured on day
120. Such d-AmB/PLGA injection was also eﬀective in established lesions (day 30), leading to 97% parasite
burden reduction, as compared with d-AmB or liposomal AmB (Ambisome®) i.l. injection containing the same
AmB dose. Pharmacokinetic studies showed that following d-AmB/PLGA injection, AmB leaked slower from non-
infected than infected ears, yet remaining in the ear tissue for as long as 30 days. Of interest, AmB was not
detectable in the circulating plasma for at least two weeks of d-AmB/PLGA injection, contrasting with the rapid
and durable (2 days) detection after free d-AmB injection. Despite the transient ear swelling and local cell
inﬁltration, no alterations in AST, ALT and creatinine serum levels was induced by d-AmB/PLGA. For its ap-
proved components, local eﬃcacy, and single-dose applicability, this novel and safe AmB microparticle depot
formulation has strong potential as a new therapy for human CL.
1. Introduction
Cutaneous (CL) and visceral (VL) leishmaniasis are Neglected
Tropical Diseases (NTDs) caused by intracellular protozoans of the
genus Leishmania. CL is the most common form of leishmaniasis, an-
nually aﬀecting 1.2 million people worldwide (Alvar et al., 2012). The
disease is characterized by chronic skin ulcers normally restricted to the
site of infected sandﬂy bite. Unlike Old-World parasite species, like L.
major and L. tropica that cause self-healing lesions, New World species
such as L. braziliensis and L. amazonensis are not normally self-healing,
and may evolve into disﬁguring Mucosal and Diﬀuse CL forms.
Currently, even the more benign localized CL form is treated sys-
temically with the same toxic drugs used with fatal VL. These include
pentavalent antimonials, pentamidine and amphotericin B (AmB),
given in one or more series of 20–30 parenteral injections that can
cause serious adverse eﬀects, and even death (Uliana et al., 2017). AmB
is the most active antileishmanial drug available for clinical use.
However, due to poor solubility, AmB must be formulated in deox-
ycholate (d-AmB) for intravenous injection, which improves solubility
but contributes to its nephrotoxic eﬀect. Liposomal formulations (e.g.
Ambisome®) have considerably decreased AmB toxicity. Due to in-
creased drug accumulation in the liver and spleen, less than 0.1% of the
injected drug reaches the skin lesion (Wijnant et al., 2018b, 2018c),
restricting Ambisome® to VL and more complicated CL cases. The only
oral drug available for leishmaniasis is miltefosine, but this too has
controversial eﬃcacy in human CL (Kevric et al., 2015) and is not yet
licensed in countries like Brazil.
There is a strong need for topical therapies for CL, particularly for
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the milder and most common cases with up to 4 ulcers not exceeding
3 cm in diameter (DNDi, 2017). Local thermotherapy is drug-free, but
requires accurate equipment and trained personnel to avoid common
burnings (López et al., 2012; Navin et al., 1990). However, drug for-
mulations for topical application have not met the expected impact.
Paromomycin-based ointment marketed in the Middle East is not ef-
fective against New World parasite species (Ben Salah et al., 2013; Sosa
et al., 2013). Likewise, a cream containing 3% of AmB (Anfoleish) had
its clinical study in Colombian CL patients discontinued because of poor
eﬃcacy (Asela et al., 2018). The development of an eﬀective antil-
eishmanial cream is a challenge since drugs must cross the strong
stratum corneum barrier of the skin to reach the parasites within the
phagolysosome of the infected macrophages in the deep layers of the
skin. Epidermis thickening that normally accompanies lesion develop-
ment is another factor that hinders drug absorption through the skin
(Bocxlaer et al., 2016). Intralesional (i.l.) injections with antimonials
aiming at bypassing epidermal permeation have proved a more eﬀec-
tive measure for local drug delivery (Silva et al., 2016). However,
periodical injections are needed to compensate for rapid drug absorp-
tion into the bloodstream and lymph vessels, which besides pain and
repeated hospital visits, may also cause systemic side eﬀects
(Esfandiarpour et al., 2012). Besides, a study in Iran showed that
weekly i.l. injections with 2mg of d-AmB for up to twelve weeks can
cure only 61% of CL patients (Goyonlo et al., 2014). In addition, there
was a risk of local necrosis due to deoxycholate emulsiﬁer. Another
clinical study in Iran showed the low eﬃcacy of intralesional injections
with deoxycholate-free liposomal AmB (Ambisome®), which was prob-
ably caused by rapid diﬀusion of the small liposomes from the lesion
(Yardley and Croft, 1997). Therefore, injections forming a local drug
depot seem to be a better alternative for localized CL.
Controlled drug release systems using biodegradable PLGA micro-
particles have been marketed for some years to treat a variety of human
diseases like cancer, diabetes, schizophrenia, and growth hormone
disorders (Wang et al., 2016). Those systems are injected in-
tramuscularly to form a local depot capable of releasing the drug during
weeks or months, impressively reducing the frequency of doses and
adverse eﬀects as compared with conventional formulations. In leish-
maniasis, we reported the synthesis and use of PLGA microparticles
loaded with an antileishmanial chalcone (CH8) for treatment of ex-
perimental CL with a single s.c. injection (Sousa-Batista et al., 2018a,b
). In the present study, we describe the design and therapeutic use of
PLGA microparticles loaded with AmB, aiming at a more rapid reg-
ulatory approval of this new antileishmanial treatment strategy.
2. Material and methods
2.1. d-AmB/PLGA preparation
Microparticles were prepared by a double emulsion and solvent
evaporation method (W1/O/W2) from a 1:10 w/w mixture of d-AmB
(Fungizone®, Abbott) and PLGA 50:50 (poly(lactic-co-glycolic acid),
Purac 504, Purasorb). Brieﬂy, 500mg of PLGA 50:50 was dissolved in
10mL dichloromethane – DCM - (oil phase). Inner aqueous phase (w1)
was prepared by dissolving 5mg of d-AmB in 1mL of distilled water. d-
AmB, not pure AmB, was used for increased solubility in water. The w1
phase was emulsiﬁed into the oil phase using a high-shear homogenizer
(Ultra-Turrax T25 Basic, Ika, Germany) at 7000 rpm for 10min. The
w1/O emulsion was added gradually dropped into 120ml of aqueous
(3%, w/w) polyvinyl alcohol (PVA, Sigma) solution under agitation.
After that, DCM in the double emulsion was evaporated under low
agitation on ice to yield d-AmB/PLGA microparticles. The obtained
microparticles (d-AmB/PLGA) were washed 3x with water by cen-
trifugation at 4000 rpm during 5min, and dried by lyophilization
(FreeZone 1 liophilizer, Labconco Corporation). Blank microparticles
(PLGA) were prepared in the same way except that no d-AmB was
added.
2.2. d-AmB/PLGA characterization
For total drug content, a dry d-AmB/PLGA sample was dissolved in
a mixture (1:2) of dimethyl sulfoxide (DMSO, Sigma-Aldrich) and
acetonitrile (Tedia). After centrifugation and 0.45 μM membrane ﬁl-
tration, AmB concentration was determined by UV-HPLC at 405 nm
using a mobile phase containing acetonitrile:aqueous 0.01% phosphoric
acid (Tedia) (60:40 v/v) ﬂowing at a rate of 1mL/min. A calibration
curve ranging from 0.25 to 50 μg/mL AmB (r > 0.999) was done at
each analysis. The encapsulation eﬃciency (EE %) was calculated as the
ratio between measured and theoretical AmB amounts, multiplied by
100%. For in vitro release ratio, 2 g of d-AmB/PLGA was added in du-
plicate to 150mL of 0.5% of polysorbate 80 and 0.1% sodium azide in
phosphate buﬀered saline (PBS, pH 7.0), maintained at 37 °C, under
60 rpm agitation. At diﬀerent time points (4 h–200 days), a sample
(100 μL) was withdrawn, ﬁltered and analyzed for AmB concentration,
as above.
The particle size distribution was measured by laser diﬀraction
(Beckman Coulter LS230) after resuspension of the solid microparticles
in water and ultrasound dispersion. The zeta potential was measured
using Zetamaster (Malvern Instruments). For scanning electron micro-
scopy (SEM), dry microparticles and AmB powder were sputtered on
double-face tape and these with gold (JFC-129 1300, JEOL) prior to
analysis in electron microscope (JPC 1100, JEOL) at 15 kV.
2.3. Parasites, mice and ethics statement
Leishmania amazonensis (strain WHOM/BR/75/JOSEFA) promasti-
gotes were maintained at 27 °C in medium M199 supplemented with
10% heat-inactivated fetal bovine serum (HIFBS, Cultilab), and used at
the stationary phase of growth. BALB/c mice (female, 23 g) were
maintained under controlled temperature, ﬁltered air, ﬁltered water,
autoclaved bedding, and commercial food at our facilities at Federal
University of Rio de Janeiro. All protocols using mice were approved by
the Federal University of Rio de Janeiro institutional Animal Care and
Use Committee (protocol number CAUAP118) under the CONCEA
(National Council for control of Animal Experiments).
2.4. Cytotoxicity to intracellular amastigotes and macrophages
For antiamastigote activity, glass coverslip-adherent mouse perito-
neal macrophages (5× 105) were incubated with 5× 106 L. amazo-
nensis promastigotes for 4 h at 34 °C in M199 plus 10% HIFCS. Then,
free parasites were removed by washing with PBS, and infected cells
incubated for further 24 h for transformation and replication as amas-
tigotes. Infected macrophages were treated with d-AmB, d-AmB/PLGA
or PLGA in equivalent AmB concentrations ranging from 0.01 μM to
100 μM (n=3) for 48 h at 37 °C. At the end of incubation time, cells
were stained with Giemsa and the total number of amastigotes in 200
macrophages by coverslip was evaluated by direct counting. The results
were analyzed by curve ﬁtting regression and expressed as IC50 (con-
centration that inhibits parasite growth by 50%).
For macrophage cytotoxicity, adherent uninfected mouse peritoneal
macrophages were treated for 48 h at 37 °C as for antiamastigote ac-
tivity. Then, the cells were centrifuged (500 rpm/5min) and the su-
pernatants collected for quantiﬁcation of released lactate dehy-
drogenase (LDH) using an assay kit (Doles, Brazil) and a microplate-
reader spectrometer (SpectraMax M5) at 490 nm. Maximum and
spontaneous release were obtained with cells cultured with 2% Triton
X-100 or culture medium alone, respectively. The results calculated as
% Speciﬁc Release= [(Maximum – Spontaneous)/(Drug –
Spontaneous)] x 100, were analyzed by curve ﬁtting regression, and
expressed as CC50 (concentration that produces 50% of speciﬁc LDH
release).
2.5. Eﬃcacy against CL
Mice were infected in the ear pinnae with 2× 106 promastigotes of
L. amazonensis. On day 10 or 30 of infection, as indicated, they were
injected intralesionally with d-AmB, d-AmB/PLGA or liposomal
AmBisome® (5 μg of AmB/10 μL of PBS, 0.2 mg/Kg), using hypodermal
needles. Controls received PLGA alone in equivalent dose (550 μg/
10 μL, 25mg/kg) or PBS alone (10 μL). Alternatively, animals treated
on day 10 were given eight intralesional injections with free d-AmB
(5 μg/10 μL each, 2x a week) on days 10–42. The eight-injection re-
gimen was chosen not only for control maximization but also to mimic
clinical studies in Iran where each CL lesion was injected with 2mg of
Fig. 1. Microparticle physical characteristics. A) PLGA and d-AmB/PLGA microparticles were analysed by Coulter LS230 for diﬀerential (Gaussian lines) and
cumulative (progressive lines) volumes. B) Data for diameter distribution, zeta potential, and encapsulation eﬃciency (E.E.). Means ± SD (n= 3).
Fig. 2. Microparticle SEM and in vitro release
kinetics. A-C) Dried d-AmB/PLGA micro-
particles were imaged by SEM in lower (A) and
higher (B) magniﬁcation to conﬁrm absence
external AmB. Dry AmB (C) is shown as control.
D) d-AmB/PLGA microparticles were incubated
in duplicate at 37 °C in PBS under mild agitation.
At the indicated times, supernatant samples
were removed for quantiﬁcation of AmB by
HPLC, followed by PBS volume replacement.
Means ± SD (n= 2).
Table 1
In vitro cytotoxicity against intracellular amastigotes and macrophages.
Samples Amastigotes IC50 (μg/ml) Macrophages CC50 (μg/ml) SIb
d-AmB 0.08 ± 0.2 2.0 ± 0.1 25.0
PLGA >100 >100 ND
Ambisomea 1.4 ± 0.3 97.0 ± 2.0 69.3
d-AmB/PLGAa 0.05 ± 0.1 2.5 ± 0.1 50.0
Means ± SD(n=3).
ND=not determined.
a AmB equivalents.
b SI (selectivity index)=CC50/IC50.
d-AmB (assuming 1mL/injection) up to 12 times on a weekly basis,
resulting in 61.4% of patients with full healing at the end of the 12th
week (Goyonlo et al., 2014). Ear thicknesses were periodically mea-
sured during infection with a caliper gauge, and lesion sizes were ex-
pressed as the diﬀerence between infected and noninfected ears. At the
end of experiments, the infected ears were photographed, and parasite
burdens were measured by limiting dilution assay (Lima et al., 1997;
Sousa-Batista et al., 2018b).
2.6. Local and systemic pharmacokinetics
For local pharmacokinetics, both uninfected and 7-day infected
mice were given a single s.c. injection with d-AmB/PLGA (5 μg in 10 μL
of PBS) in the ear pinnae. At diﬀerent time points thereafter (30min–90
days), the mice were killed, and the ears individually homogenized in
1mL of acetonitrile. After centrifugation (10.000 rpm/10min), the su-
pernatants were dried, and assayed for AmB quantiﬁcation using UV-
HPLC, as described in item 2.2.
For systemic pharmacokinetics, uninfected mice were given a single
s.c. injection with d-AmB/PLGA or d-AmB (5 μg in 10 μL of PBS) in the
ear pinnae. At diﬀerent time points (30min–15 days), their blood was
collected in heparinized tubes, centrifuged, and the obtained plasma
treated with acetonitrile and phosphoric acid (pH 4). After centrifuga-
tion (1500 rpm/2min), AmB concentration was quantiﬁed by UV-HPLC
as above.
2.7. Systemic toxicity
Mice were infected with L. amazonensis. On day 30, they were given
a single intralesional injection with PLGA, d-AmB, liposomal AmB
(AmBisome®) or d-AmB/PLGA (5 μg in 10 μL of PBS). In the positive
control group (n=5), mice were intraperitoneally injected with 200 μL
of 1% carbon tetrachloride (CCl4) in soybean oil three days before
animal killing. On day 90 of infection, the sera were collected and as-
sayed for AST, ALT, and creatinine as parameters of liver and kidney
toxicity, using a colorimetric commercial kit (Doles, Brazil) adapted for
microvolumes. The positive-control sera were taken from mice which
received 200 μL of 1% carbon tetrachloride (CCl4) in soybean oil by the
intraperitoneal route 3 days before serum collection (Otsuka et al.,
2002).
2.8. Cutaneous sensitization
That was evaluated using an adapted mouse ear-swelling test
(MEST) (Gad, 1994). Mice were sensitized 9, 7 and 5 days earlier with
s.c. injections in the shaved hump with d-AmB, d-AmB/PLGA, or Am-
Bisome® (5 μg of AmB/dose), or PBS alone (10 μL). Positive controls
were topically applied with oxazolone (0.5% in acetone) in the same
days. On day 0, mice were injected/applied in the ear pinnae with the
same sensitizing dose. At diﬀerent time points thereafter (20min–72 h),
the ear thicknesses were periodically measured with a caliper gauge,
and edema was expressed as the diﬀerence between challenged and
non-challenged ears. Edema was considered positive when 20% su-
perior than PBS-injected ears (Gad, 1994).
2.9. Histopathology
Non-infected mice were given a single s.c. injection in the ear
pinnae with d-AmB/PLGA (5 μg of AmB in 10 μL of PBS). After diﬀerent
time points (4 h, 1 day and 30 days), the ears were removed and pre-
served in Millonig ﬁxative (pH 7.4). Longitudinal 4 μm-thick ear sec-
tions were stained with hematoxylin and eosin, and photographed
under light microscope (Nikon eclipse - Ti).
2.10. Statistical analysis
One-way analysis of variance and the Bonferroni posttest were
performed to demonstrate statistical diﬀerences (P < 0.05). To com-
pare the diﬀerence between two groups, a nonparametric t-test was
used. All statistical analyses used GraphPad Prism 6 software.
3. Results and discussion
Currently, the conventional chemotherapy of human CL is based on
multiple injections with systemically toxic drugs, urging safer and more
active local treatments. Previously, we successfully used PLGA micro-
particles loaded with the active chalcone CH8 to promote local pha-
gocytosis and sustained release for localized treatment of murine CL.
Aiming at improving formulation eﬃcacy and clinical licensing, we
proposed here the use of PLGA microparticles loaded with AmB, the
most active antileishmanial in clinical use. We sought to obtain PLGA
particles with a size distribution that included both smaller particles
(≤6 μm) for rapid macrophage internalization (Sousa-Batista et al.,
2018a,b), and larger particles (≥10 μm) for extracellular depot
(Gaumet et al., 2008). With ﬁnelly adjusted double emulsion and
Fig. 3. Eﬃcacy of single-dose treatment with d-AmB/PLGA in early CL.
Mice were infected with L. amazonensis in the ear pinna. On day 10 of infection,
they were given a single intralesional injection with d-AmB/PLGA (5 μg of
AmB), PLGA (500 μg) or PBS vehicle (10 μL). d-AmB (5 μg/dose) was given by
the same route twice a week (total 8 doses). Lesion sizes were measured on the
indicated days (A). Parasite loads were determined on day 120 post infection in
the ear (B) and draining lymph nodes (C) by limiting dilution assay.
Means ± SD (n = 5). ***p < 0.01 and *p < 0.5 in relation to d-AmB 8X.
solvent evaporation conditions, we obtained blank PLGA and drug-
loaded d-AmB/PLGA microparticles with adequate unimodal size dis-
tribution within the aimed range (Fig. 1A). d-AmB/PLGA sizes averaged
5.5 μmat D(4.3) and 10.3 μmat D(90) with 2.5 span value (Fig. 1B).
The relatively weak d-AmB/PLGA negative charge (−10.6mV) was
also suitable to promote phagocytosis, prevent aggregation, and avoid
cytotoxicity as observed with cationic particles (Fröhlich, 2012;
Nicolete et al., 2011).
Diﬀerent from chalcone CH8 that is readily entrapped in PLGA
thanks to its high lipophilicity, AmB is amphiphilic, and more diﬃcult
to entrap. Despite the high process entrapment eﬃciency (89.9%), a
maximum of 0.9% of drug loading in the microparticle was achieved.
Fig. 4. Eﬃcacy of single-dose treatment with d-AmB/PLGA in established CL. Mice were infected in the ear with L. amazonensis. On day 30 of infection, they
were given a single intralesional subcutaneous injections with d-AmB, AmBisome® or d-AmB/PLGA (5 μg of AmB each). Controls were given PLGA (500 μg) or PBS
vehicle (10 μL). A) Lesion sizes were measured on the indicated days. B) Representative lesion pictures on day 90. C) Parasite loads in the ear, and D) draining lymph
nodes, measured on day 90 by limiting dilution assay. Means ± SD (n = 5). ***p < 0.01 in relation to d-AmB 1X.
Fig. 5. Local and systemic pharmacokinetics. (A) Infected and non-infected mice were treated in the ear with a single dose of d-AmB/PLGA (5 μg of AmB). B) Non-
infected mice were treated with d-AmB or d-AmB/PLGA (5 μg of AmB each). After the indicated time points, AmB was quantiﬁed in the ear or plasma by HPLC/UV at
405 nm. Means ± SD (n= 3).
SEM analysis showed that the particles were spherical and smooth, with
scarce external drug crystals, suggesting that most of the added AmB is
inside the particle (Fig. 2 A and 2B vs free AmB crystals in 2C). The in
vitro drug release kinetics occurred in biphasic mode (Fig. 2D). During
the ﬁrst 24 h, a fast release of 7% of the total drug was observed,
probably due to external drug. Thereafter, a controlled drug release was
observed, reaching 25% after one month, and 80% after two months,
hypothetically adequate for CL treatment with a single dose. The ob-
served in vitro AmB release rate is slower than reported with AmB-
loaded PLGA nanoparticles aiming at oral delivery (Italia et al., 2009).
In that study, AmB was released faster (∼60% of the drug in 25 days),
suggesting that the larger particle size used here is important for a more
prolonged release.
The in vitro antileishmanial activity of d-AmB/PLGA was in-
vestigated in L. amazonensis-infected macrophages. The anti-amastigote
activity obtained with d-AmB/PLGA was similar to that of free d-AmB
(IC50= 0.05 μg/mL vs 0.08 μg/mL), and slightly higher than that of
liposomal AmB (Ambisome®, IC50= 1.4 μg/mL), as shown in Table 1.
That contrasts with the lower activity of entrapped CH8/PLGA in re-
lation to free CH8 (Sousa-Batista et al., 2018b), explained by the higher
aﬃnity of CH8 for PLGA than AmB, supported by higher entrapment
ratio of the former (10% and 0.9% respectively). The indirect con-
tribution of macrophage activation is unlike, since blank PLGA was
devoid of antileishmanial activity. The lower Ambisome® activity may
be due to its variable ability to be endocytosed by macrophages and/or
the high AmB aﬃnity for the liposomal distearoylphosphatidylglycerol
and cholesterol (Legrand et al., 1996; Voak et al., 2018; Yardley and
Croft, 1997). Since AmB activity is related to a disruptive eﬀects in the
cell membrane lipids (Grela et al., 2018), the slow rate of AmB transfer
from the liposome to the cell membrane may also have accounted to
reduced Ambisome® reduced activity. Anyway, the ﬁnding that d-AmB/
PLGA was two-fold more selective than free d-AmB (SI= 50 and 25,
respectively) is promising. A more prolonged in vitro assay to allow for
greater intracellular drug release would possibly provide a greater
diﬀerential eﬀect between d-AmB/PLGA and free d-AmB.
The eﬃcacy of a single-dose treatment with d-AmB/PLGA was
evaluated in the BALB/c mouse model of infection with L. amazonensis.
Treatment was carried out either in the early stage of infection for
maximization, or in established lesions for a more real situation. All
formulations were tested intralesionally in the same AmB dosage (5 μg/
animal, 0.2 mg/kg). For early treatment, on day 10 post infection mice
were given a single dose of d-AmB/PLGA or the ﬁrst of eight injections
with free d-AmB. Multiple injections with free d-AmB eﬀectively con-
trolled lesion growth only during treatment (days 10–42 of infection)
(Fig. 3). On the other hand, a single d-AmB/PLGA injection signiﬁcantly
delayed lesion growth for at least 80 days (day 90 of infection). Still,
almost 4 months after treatment (day 120 of infection), lesions were
37% smaller, and the parasite burdens in the ear and draining lymph
nodes were 85% and 78% smaller than PBS controls, respectively. The
observed lesion recrudescence after 90 days of d-AmB/PLGA injection
was possibly due to: i) After 90 days of injection, no more drug was
locally available; ii) The BALB/c mouse model used is unable to mount
an eﬀective immune response. Although BALB/c mice are well-estab-
lished models for antileishmanial drug evaluation, most studies tend to
evaluate eﬃcacy (parasite burden) soon after the end of treatment,
because remaining parasites cannot be controlled by immunity (Mears
et al., 2015; Mendonça et al., 2018).
Treatment was also evaluated in established 30-day lesions, when
animals received a single injection with d-AmB/PLGA, Ambisome®, or
d-AmB, all containing 5 μg of AmB for comparison. Controls received
blank PLGA or PBS alone. No pure AmB could be included due to AmB
precipitation in aqueous solutions. As seen in early treatment, d-AmB/
PLGA eﬀectively controlled lesion growth for at least 60 days (Fig. 4).
At that stage when lesions reached 400 (mm x 10−2) in thickness, the
experiments ended in accordance with the ethical terms of our animal
license. The lesion sizes were 69% smaller than PBS controls, while the
parasite burdens in the ear and draining lymph nodes were signiﬁcantly
reduced (97% and 87% reduction, respectively). Unlike all the other
treatments, ears given d-AmB/PLGA were non-ulcerated and healed.
Ambisome® was only transiently eﬀective, possibly due to rapid outﬂow
of the small liposomes from the site of infection (Yardley and Croft,
1997; Wijnant et al., 2018c). As observed with eight injections (Fig. 3),
Fig. 6. Systemic toxicology. Thirty-day infected mice were given a single dose
of the indicated AmB formulations or controls, as for Fig. 4. After sixty days of
treatment, sera were collected and individually assayed for AST (A), ALT (B),
and creatinine (C). Positive control (1% of CCl4) was given by intraperitoneal
injection on day 87. Means ± SD (n=5).
Fig. 7. Cutaneous hypersensitivity. Mice were pre-sensitized in the back by
3 s.c. injections with d-AmB, d-AmB/PLGA (5 μg of AmB) or PBS (10 μL) alone,
on days −9, −7 and −5. Oxazolone was applied topically on the same days.
On day 0, their ear pinnae was challenged in the same way, and the resulting
swelling measured in the indicated days. The dashed line indicates sensitization
threshold, that is 20% of achieved with 0.5% oxazolone. Means ± SD (n= 5).
a single injection with free d-AmB was ineﬀective. In both the early and
late treatment models, empty PLGA was inert against parasite growth,
indicating that parasite killing is due to AmB, but a synergistic PLGA
eﬀect leading to macrophage activation cannot be discarded (Nicolete
et al., 2011).
d-AmB rather than pure AmB was incorporated into PLGA micro-
particles due to the poor AmB solubility in the process-compatible
solvents. The 5 μg AmB dose (0.22 mg/kg) was chosen for safety rea-
sons since local necrosis was produced with 10 μg and 50 μg of d-AmB
injected twice a week for 2 weeks (our unpublished observation). Such
toxicity was likely due to deoxycholate (Dayan et al., 2018), and warns
against local therapy with d-AmB (eg Fungizone®, Anforicin B®). To
reduce potential toxicity, we are presently adjusting the synthesis
process to increase drug encapsulation rate in the absence of deox-
ycholate. A previous study used a polymethacrylic acid (PMA) hydrogel
as a vehicle to inject deoxycholate-free AmB into mouse lesions caused
by L. major to promote accelerated healing (Corware et al., 2011).
However, considering the high anti-amastigote activity of the for-
mulation (IC50= 0.08 μg of AmB/mL), much higher individual doses
containing 135 μg of AmB (total of 400 μg) were needed compared with
the 5 μg single dose reported here.
The d-AmB/PLGA local pharmacokinetics was studied in both un-
infected and 7-day infected mouse ears. Independently of infection,
AmB was released from the ears within 30 days (Fig. 5A), compatible
with the PLGA 50:50 degradation time (Makadia and Steve, 2011).
Drug release was faster in vivo than in vitro (80 days, Fig. 2), likely due
to degrading enzymes in the living tissue. We observed lower AmB
retention in the infected ears than healthy ears, possibly caused by the
higher vascular permeability of infected tissue allowing faster leakage.
This is compatible with a recent report showing that the stage of murine
CL has profound impact on skin access of intravenously delivered d-
AmB (Wijnant et al., 2018a). In that study, 24 h after administration, d-
AmB accumulation in established lesions was higher than in healthy
skin. Thus, in a reverse way we demonstrate that local tissue in-
ﬂammation caused by infection may facilitate drug permeation out of
CL skin lesion. Therefore, it will be important to take into account the
stage of lesion development to calculate treatment duration.
Systemic pharmacokinetics was also studied, where AmB plasma
concentration following a single intralesional injection with d-AmB/
PLGA was compared with free d-AmB (Fig. 5B). While AmB was readily
detectable in the plasma within 1 h following d-AmB injection, reaching
a peak accumulation within 12 h, it remained undetectable following d-
AmB/PLGA injection throughout the 15-day follow up. The observation
that d-AmB/PLGA does not detectably leaks to the circulation is com-
patible with a sustained release depot together with phagocytosis by
local macrophages. On the other hand, the rapid leakage to the blood
following d-AmB injection corroborates with the low eﬃcacy of i.l.
injections (Figs. 3 and 4). Although the pharmacokinetics of locally
injected liposomal AmB (Ambisome®) was not studied here, it is likely
that the small liposomes (∼80 nm) will also escape from the lesion to
the blood either directly or through lymphatic drainage (Wijnant et al.,
2018c). These local and systemic pharmacokinetic ﬁndings conﬁrm the
sustained local release and systemic safeness.
Despite its approved components, the new AmB formulation and use
demands safety assessment (Wang et al., 2016). Thus, all AmB for-
mulations used here were compared for increased plasma ALT, AST and
creatinine levels after a single intralesional injection. No treatment
including d-AmB/PLGA resulted in detectable plasma levels, indicative
of lack of liver, heart and kidney toxicity (Fig. 6). For skin reactivity
following a single s.c. injection with d-AmB/PLGA, two tests were used:
i) the mouse ear-swelling test (MEST) indicative of cutaneous sensiti-
zation, and ii) histological analysis. Non-infected animals were used to
avoid dual treatment and infection eﬀects. For MEST, mice were sen-
sitized with three weekly s.c. injections in the back, and challenged 5
days later in the ear. A transient swelling response starting after 2 h and
decreasing after 20 h was seen in mice receiving Ambisome®, d-AmB/
PLGA and PLGA (Fig. 7). The reaction, maximized by sequential pre-
sensitization, is considered mild in comparison with the reference agent
oxazolone. For histological analysis, ear tissue slices were prepared
after 4 h, 24 h and 30 days of d-AmB/PLGA injection. Fig. 8 shows re-
presentative slides of 3 mice in each time point. As early as 4 h, the ears
were thickened with cellular inﬁltrate and edema, compatible with the
swelling seen in Fig. 7. The inﬂammatory inﬁltrate increased at 24 h, as
seen by increased numbers of purple nuclei. Thirty days after injection,
the ears presented normal morphological structure, indicating that the
inﬂammatory response waned. Similar ﬁndings were found in ears in-
jected with PLGA alone (not shown), in accordance with the swelling
response in Fig. 7, and previous studies demonstrating the slight in-
ﬂammatory eﬀect of PLGA microparticles (Barsoum et al., 1997; Xie
et al., 2015). No microparticles could be seen in the histological sec-
tions, because the polymer degrades with the tissue ﬁxatives.
The single subcutaneous injection contained 5 μg of AmB and
550 μg of PLGA (0.23 mg of AmB/Kg and 25mg of PLGA/Kg of mouse
body weight, 22 g). Dose translation from mouse to human using the
body surface area normalization method (Nair and Jacob, 2016) pro-
vides 0.02mg of AmB/Kg and 2.1 mg of PLGA/Kg of human body
weight (60 Kg). Such translated AmB dose is compatible with its clinical
use, based on studies conducted in Iran and India, where CL patients
received weekly i.l. injections with 0.04mg of d-AmB/Kg (Goyonlo
et al., 2014; Mushtaq et al., 2016). As to the polymer, PLGA-based drug
products like Risperdal Consta® (131mg), Lupron Depot® (120mg) and
Trelstar Depot® (170mg) used to treat schizophrenia, prostate cancer
and endometriosis, respectively, are given as single doses of approxi-
mately 2.2 mg of PLGA/Kg, which is similar to used here. Therefore,
both AmB and PLGA doses used here are clinically compatible. For
human administration, it is expected that treatment will be accom-
plished by perilesional injections with small volumes of d-AmB/PLGA a
single time, diﬀerent from the present inﬁltration with 1–3mL of Glu-
cantime in diﬀerent times.
In summary, this study describes the safe and eﬀective use of AmB
for one-dose localized treatment of CL in mice, not achievable with
marketed deoxycholate and liposomal formulations. Such d-AmB/PLGA
Fig. 8. - Histopathological analysis. Mice were given a single s.c. injection in the ear pinna with d-AmB/PLGA (5 μg of AmB), or were left untreated (A). After 4 h
(B), 1 day (C) or 30 days (D) post injection, longitudinal ear sections were obtained and stained with H&E. The inﬂammatory inﬁltrate is shown with arrows.
Representative photographs of triplicate samples are shown. Bars= 100 μm.
microparticles platform has strong potential for ready licensing, and
revolutionizing the treatment of localized and uncomplicated CL, the
commonest form of leishmaniasis. Besides, the d-AmB/PLGA platform
is potentially transposed to systemic treatment of VL and systemic
mycosis.
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